Nestlé divests its peanut allergy treatment business
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specialises in the diagnosis and treatment of allergies. The transaction was closed upon signing.
Last year, Nestlé announced it would conduct a strategic review of Palforzia. It will now receive milestone payments and ongoing royalties from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said Nestlé is confident that Stallergenes Greer will take Palforzia forward, allowing Nestlé Health Science to focus on its strengths and growth drivers.
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
TasFoods Ltd has gone into voluntary administration
Following the unsuccessful attempt to sell its poultry brand, Nichols Poultry, TasFoods Ltd...
Fonterra CEO Miles Hurrell announces resignation
Fonterra Co-operative Group Ltd has today (16 March 2026) announced that Chief Executive Officer...
Australian beverage sector has a record summer
There was a summer surge of revenue for Aussie beverage manufacturers in Q4 2025, according to...
